NGR-hTNf plus doxorubicin in recurrent ovarian cancer

Domenica Lorusso, Paola Malaguti, Giovanni Scambia, Claudio Bordignon, Francesco Raspagliesi

Research output: Contribution to journalArticlepeer-review


Ovarian cancer is the most lethal gynaecological cancer. Despite surgery and first-line chemotherapy, tumours recur in 60-70% of cases and prognosis is poor. Several studies have indicated that the cytokine tumour necrosis factor (TNF) has antitumour activity when given systematically, but its high toxicity has limited its use. Peptides containing the aspargine-glycine-arginine motif (NGR peptides) selectively bind to the aminopeptidase N ligand CD13, which is overexpressed in the cells of tumour blood vessels. It has been found that the combination of an NGR peptide and human TNF (NGR-hTNF) has the ability to increase intratumoural doxorubicin distribution by altering the tumour vasculature. In this article, we describe the activity and toxicity profile of NGR-hTNF plus doxorubicin as a combination treatment for recurrent ovarian cancer.

Original languageEnglish
Pages (from-to)107-110
Number of pages4
JournalEuropean Oncology and Haematology
Issue number2
Publication statusPublished - May 2012


  • Doxorubicin
  • Ngr-hTNf
  • Platinum-resistant
  • Platinum-sensitive
  • Recurrent ovarian cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'NGR-hTNf plus doxorubicin in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this